×

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the Company will present at the following upcoming conferences:

  • Baird's 2014 Health Care Conference, Wednesday, September 3, 2014 at 10:15 a.m. ET. A corresponding webcast of this presentation can be accessed by visiting:

    http://wsw.com/webcast/baird39/cris
  • Rodman & Renshaw 16th Annual Global Investment Conference, Wednesday, September 10, 2014 at 11:15 a.m. ET. A corresponding webcast of this presentation can be accessed by visiting:

    http://wsw.com/webcast/rrshq24/cris

Dr. Ali Fattaey, President and Chief Executive Officer, will provide an overview of Curis' proprietary cancer programs including its dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor, CUDC-907, and its antagonist of inhibitor of apoptosis (IAP) proteins, CUDC-427. Dr. Fattaey will also provide an overview of Curis' partnered programs including Erivedge® (vismodegib), a hedgehog pathway inhibitor developed under collaboration with Genentech and Roche that is the only approved medicine for patients with advanced basal cell carcinoma, and Debio 0932, an HSP90 inhibitor that is in clinical development by Curis' collaborator Debiopharm.

The presentations will be archived shortly after the live events and available for 30 days following each conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.

About Curis, Inc.

Curis is an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor, and CUDC-427, a small molecule antagonist of IAP proteins. Curis is also engaged in a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. Curis partner Debiopharm is studying HSP90 inhibitor Debio 0932 in patients with advanced lung cancer. For more information, visit Curis' website at www.curis.com

CONTACT: Mani Mohindru, Ph.D. Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 mmohindru@curis.com Michael P. Gray Chief Business and Financial Officer Curis, Inc. 617-503-6632 mgray@curis.com

Source:Curis, Inc.